Introduction {#sec1-1}
============

Since the late 1980s, there has been a rapid increase in glycopeptide resistance. While most of these reports have come from developed countries, it appeared that there had been a lag in development of glycopeptide resistance of enterococci in developing countries, probably due to low consumption of glycopeptide antibiotics as they are relatively expensive and the problems of Methicillin Resistant Staphylococcus aureus (MRSA) and Clostridium difficile infection (CDI) have not been so prominent in these areas.

In Nigeria, the role of enterococci in clinical infections has been poorly documented. Earlier reports had suggested that resistance to glycopeptides among enterococci had not emerged[@ref1]. However, there have been recent reports of Vancomycin resistant enterococci (VRE) being isolated from clinical specimen and hands of health care workers in other centers in western Nigeria[@ref2],[@ref3].

Since enterococci are part of the normal intestinal flora of humans, the gut provides a conducive environment for development and transfer of antimicrobial resistance determinants hence gastrointestinal colonization precedes infection in many cases[@ref4]. Also, the recommendations for preventing the spread of Vancomycin resistance by the Hospital Infection Control Advisory Committee (HICPAC) of the US Centers for Disease Control include periodic culture surveys of stools or rectal swabs of patients at high risk for VRE infection or colonization[@ref5]. Routine laboratory testing of all enterococcal isolates for Vancomycin resistance, also recommended by HICPAC, is not being practiced in most clinical laboratories in Nigeria due to the perceived absence or low incidence of Vancomycin resistance among enterococcal isolates. This practice may be masking the identification of emerging Vancomycin resistant enterococcal strains.

We report a surveillance study carried out among patients on prolonged admission (over seven days) in Lagos University Teaching Hospital, a tertiary hospital in south western Nigeria.

Methods {#sec1-2}
=======

Study Subjects {#sec2-1}
--------------

Between February and August 2013, patients on admission for seven days and over across medical, surgical and pediatric wards were recruited. Rectal swabs were collected from patients after obtaining informed consent by the investigators, other medical personnel or the patients themselves. Information on clinical condition, antibiotic consumption, invasive procedures and other risk factors was also recorded.

Sample Processing {#sec2-2}
-----------------

The swabs were inoculated into bile esculin broth containing 6mg/ml of Vancomycin for 48 hours and then sub-cultured onto bile esculin agar. Black coloured colonies which were gram positive and catalase negative were transferred to blood agar plates for further identification.

Species Identification {#sec2-3}
----------------------

Further testing of isolates was carried out at the Institute of Medical Microbiology and Infections Epidemiology, Leipzig University, Leipzig, Germany. Isolates were identified by matrix-assisted laser desorption/ionization time - off light (MALDI-TOF) Mass spectrometry using VITEK2 MS system (Biomerieux, France) and verified by specie specific enterococcal ddl PCR[@ref6]. MALDI TOF Mass spectrometry is a mass spectrometry based technology that offers accurate, rapid, and inexpensive identification of microorganisms. Briefly, bacterial colonies are removed from agar culture plates, mixed with an excess of UV-absorbing matrix, and dried on steel target plates. The dried preparations are exposed to laser pulses, resulting in energy transfer from the matrix to the nonvolatile analyte molecules, with desorption of analyte into the gas phase. The ionized molecules are accelerated by electric potentials through a flight tube to the mass spectrometer, with separation of the biomarkers determined by their mass/charge ratio. The profile of biomarkers is then compared with profiles of a collection of well characterized organisms[@ref7]. *vanC* genotype was determined by identification of organisms as *E. gallinarum* and *E. casseliflavus* since these species express the *vanC* genotype constitutively.

Antimicrobial Susceptibility Testing {#sec2-4}
------------------------------------

MIC to selected antibiotics (Vancomycin, Teicoplanin, Ampicillin, Gentamicin, Linezolid and Ciprofloxacin) was determined by the E-test and interpreted according to the CLSI guidelines[@ref8].

PCR {#sec2-5}
---

DNA was extracted from overnight cultures suspended in TE buffer using the MagNa Pure 96 system (Roche)[@ref9],[@ref10]. PCR assay for Vancomycin resistance genes was carried out using standard protocols. Previously described primers were used[@ref6].

Statistical Analysis {#sec2-6}
--------------------

Associations between risk factors and colonization were tested with Chi square using SPSS statistics 17.0.0 (SPSS Inc., Chicago, Ill.). A *p* value of less than 0.05 was regarded as statistically significant.

Ethical Issues {#sec2-7}
--------------

This study was reviewed and approved by the Research and Ethics Committee of the Lagos University Teaching Hospital before commencement. Informed consent was obtained from all participants before specimen collection.

Results {#sec1-3}
=======

Rectal swabs were collected from 319 patients, 165 on surgical wards, 87 from medical and 67 from pediatric wards. Of the total number of patients surveyed, 165 were males. The ages of participants ranged from 0 to 87 years with a mean age of 34.48 years. Mean duration on admission was 49.13 days. [Table 1](#T1){ref-type="table"} shows the demographic and clinical characteristics of patients surveyed in this study.

###### 

Demographic and Clinical characteristics of patients surveyed

  Variable                     VRE     Total (n=319)   *P*[\*](#t1f1){ref-type="table-fn"}   
  ---------------------------- ------- --------------- ------------------------------------- -----------------------------------------
  Mean age                     33.91   47.23           34.48                                 0.24^[†](#t1f2){ref-type="table-fn"}^
  Male                         161     4               165                                   0.106
  Female                       145     9               154                                   
  Ward                                                                                       
  Male surgical                85      3               88                                    0.031
  Female surgical              74      3               77                                    
  Male medical                 39      1               40                                    
  Female medical               41      6               47                                    
  Pediatric                    36      0               36                                    
  Pediatric surgery            31      0               31                                    
  Mean duration on admission   50.00   27.50           49.13                                 0.313^[\*](#t1f1){ref-type="table-fn"}^
  Tuberculosis                 13      0               13                                    0.443
  Malignancy                   52      1               53                                    0.333
  Diabetic                     22      0               22                                    0.388
  Renal                        16      1               17                                    0.516
  Invasive device present      110     6               116                                   0.318
  Foley catheter               81      6               87                                    0.716
  Chest tube                   16      0               16                                    
  CV line                      8       0               8                                     
  Ventilator                   2       0               2                                     
  Tracheostomy                 3       0               3                                     
  Anti-neoplastic therapy      19      0               19                                    0.443
  Surgery                      130     5               135                                   0.505
  Used Antibiotics             288     12              300                                   0.557

ANOVA

Chi square/Fisher's exact test

Thirteen VRE strains were isolated; one *vanA E. faecium*, two *vanB E. faecium*, nine *E. gallinarum* and one *E. casseliflavus* ([Table 2](#T2){ref-type="table"}). Univariate analysis for risk factors associated with VRE colonization was only significant for the ward of admission (p=0.031) ([Table 1](#T1){ref-type="table"}).

###### 

Distribution of VRE isolates by genotype and specie

  Genotype   Specie               Number
  ---------- -------------------- --------
  *vanA*     *E. faecium*         1
  *vanB*     *E. faecium*         2
  *vanC1*    *E. gallinarum*      9
  *vanC2*    *E. casseliflavus*   1
                                  
  Total                           13

The antimicrobial susceptibility pattern of enterococcal isolates carrying *vanA, vanB* and *vanC* genes are shown in [table 3](#T3){ref-type="table"}. The *vanA* isolate showed high level resistance to Vancomycin (MIC \>256μg/mL) and teicoplanin (MIC = 48μg/mL) and was also resistant to ampicillin and ciprofloxacin. It was susceptible to linezolid and did not display high level resistance to gentamicin. Both *vanB* isolates showed intermediate resistance to Vancomycin (MIC = 8μg/mL) and were susceptible to teicoplanin. They were also resistant to ampicillin and ciprofloxacin and displayed high level resistance to gentamicin, but susceptible to linezolid. The *vanC* isolates showed Vancomycin MIC ranging from 1μg/mL to 8μg/mL and teicoplanin MIC \<2μg/mL.

###### 

Antimicrobial susceptibility profile of Enterococcus isolates carrying the *vanA, vanB, vanC1* or *vanC2* genes.

  ID   Specie               Genotype   Va      Te     Am      Ci     Li     HLGR
  ---- -------------------- ---------- ------- ------ ------- ------ ------ -------
  A    *E. faecium*         *vanA*     \>256   48     \>256   \>32   1.5    12
  B    *E. faecium*         *vanB*     8       1      \>256   \>32   0.5    \>512
  C    *E. faecium*         *vanB*     8       0.38   \>256   \>32   1.5    \>512
  D    *E. gallinarum*      *vanC1*    0.5     0.5    1       4      2      8
  E    *E. gallinarum*      *vanC1*    6       1.5    0.75    \>32   0.75   \>512
  F    *E. gallinarum*      *vanC1*    6       0.75   1.5     0.75   1      3
  G    *E. gallinarum*      *vanC1*    6       1      0.5     1      1      2
  H    *E. gallinarum*      *vanC1*    4       1      0.75    \>32   0.5    \>512
  I    *E. gallinarum*      *vanC1*    0.38    0.5    2       2      1.5    3
  J    *E. gallinarum*      *vanC1*    8       0.75   2       3      2      4
  K    *E. gallinarum*      *vanC1*    4       0.75   0.75    \>32   0.75   2
  L    *E. gallinarum*      *vanC1*    4       1      0.5     0.75   0.75   2
  M    *E. casseliflavus*   *vanC2*    8       0.75   0.125   16     0.75   1.5

Va: Vancomycin, Te: Teicoplanin, Am: Ampicillin, Ci: Ciprofloxacin, Li: Linezolid, HLGR: High Level Gentamicin Resistance

Discussion {#sec1-4}
==========

The rapid spread of Vancomycin-resistant Enterococci (VRE) which occurred in Europe and the USA in the 1990s was driven by overuse of glycopeptides in animal farming in Europe and in clinical practice in the US[@ref11],[@ref12]. In Africa, there have been very few reports of VRE, most being from South Africa. VRE cause a wide variety of infections involving the urinary tract, wound, bloodstream among other sites most commonly in hematological malignancy patients and transplant recipients.13 These cases are increasing in Nigeria[@ref14]-[@ref16].

This is the first report from Nigeria using molecular methods for differentiation of enterococci and for the determination of their resistance mechanisms. We conducted surveillance for VRE among patients admitted for 7 days and above in a tertiary hospital in South Western Nigeria. VRE were isolated from 13 (4.07%) of 319 patients screened. This is much lower than rates reported from South Africa[@ref17]. However, this comparison may not be accurate because of differences in the characteristics of the populations studied. This finding is significant when compared to an earlier study in this center which showed no resistance to Vancomycin among enterococci[@ref1] although only clinical isolates of *E. faecalis* where studied. Other studies from western Nigeria have reported Vancomycin resistance in 43% of hospital acquired infections due to *E. faecalis*[@ref2] and 17.43% of 568 *E. faecalis* isolated from the hands of healthcare workers[@ref3]. These results were obtained using phenotypic methods.

The clinical data of patients colonized with enterococcal isolates carrying Vancomycin resistance genes are shown in [table 4](#T4){ref-type="table"} while the number of patients surveyed who were receiving different classes of antibiotics is shown in [table 5](#T5){ref-type="table"}.

###### 

Clinical data of the patients with enterococcus isolates carrying a gene element of Vancomycin resistance

  ID   Age   Sex   Ward       Duration on admission (days)   Primary condition                               Antibiotics administered                                        Invasive device     TWBC   Surgical intervention    Others     VRE type
  ---- ----- ----- ---------- ------------------------------ ----------------------------------------------- --------------------------------------------------------------- ------------------- ------ ------------------------ ---------- ----------
  A    48    M     Medical    52                             Interstitial lung disease                       Amoxicillin-Clavulanate, AntiTB                                 None                6.1    None                                A
  B    70    F     Medical    17                             Cerebrovascular disease                         Levofloxacin                                                    None                NA     None                                B
  C    48    F     Medical    22                             Hyperglycemic crisis, DVT and tibial fracture   Ceftriaxone, levofloxacin, metronidazole                        Urethral catether   10.0   None                                B
  D    69    F     Medical    40                             Autoimmune hemolytic anaemia                    None                                                            None                6.3    None                                C1
  E    25    F     Medical    21                             Acute exarcebation of chronic kidney disease    Ceftriaxone, levofloxacin, metronidazole                        Urethral catether   8.5    None                     Dialysis   C1
  F    38    F     Surgical   19                             Breast cancer                                   Ceftriaxone, metronidazole, amoxicillinclavulanate                                  13.3   None                                C1
  G    27    M     Surgical   28                             Intestinal obstruction                          Levofloxacin, metronidazole, amoxicillinclavulanate             Urethral catether   15.2   Exploratory laparotomy              C1
  H    48    F     Surgical   12                             Head injury                                     Ceftriaxone, Cefixime                                           Urethral catether   5.0    Craniotomy                          C1
  I    25    F     Medical    17                             Sepsis                                          Ceftriaxone, meropenem, metronidazole, amoxicillinclavulanate   None                24.6   None                                C1
  J    27    M     Surgical   48                             Chronic leg ulcer                               Ceftriaxone, levofloxacin, ampicillinsulbactam                  None                29.9   Skin grafting                       C1
  K    64    F     Medical    20                             Paraparesis                                     Levofloxacin, metronidazole, amoxicillinclavulanate             Urethral catether   13.8   None                                C1
  L    59    F     Surgical   22                             Leg pain                                        Ceftriaxone                                                     Urethral catether   17.2   None                                C1
  M    66    M     Surgical   31                             Tibial fracture due to gunshot                  Levofloxacin, metronidazole, Ceftriaxone, Cefixime              None                5.0    Open reduction                      C2

TWBC - Total White Blood Cell Count, M - Male, F - Female, NA- Not available

###### 

Antibiotic consumption pattern of patients surveyed

  ANTIMICROBIAL                            COUNT   \%
  ---------------------------------------- ------- ------
  Cephalosporins                           215     67.4
  Metronidazole                            185     58.0
  Quinolones                               162     50.8
  Penicillins                              87      27.3
  Carbapenems                              22      6.9
  Anti-tuberculous                         22      6.9
  Glycopeptides                            8       2.5
  Antifungal/Antiretroviral                5       1.6
  Others[\*](#t5f1){ref-type="table-fn"}   48      15
  None                                     19      6.0

Macrolides, Aminoglycosides, Antifolates, Nitrofurantoin, etc.

The low prevalence of VRE in this center may not be unconnected with the low consumption of Vancomycin among patients in this center. Only 2.5% of subjects studied had received Vancomycin. However, there was high consumption of cephalosporin (67.4% of subjects) and metronidazole (58.0% of subjects) which have also been implicated in the acquisition of VRE[@ref18].

Both *vanB* isolates were recovered from patients admitted in the same ward suggesting nosocomial spread. Although *vanB* demonstrates lower level Vancomycin resistance and is more commonly susceptible to Teicoplanin, it has been shown to possess high potential for nosocomial transmission and conjugal transfer[@ref19]-[@ref21]. *VanA* VRE have been the more predominant genotype in Europe and the US, but *vanB E. faecium* may be more common in Africa as was found in South Africa[@ref17]. Most microbiological studies of enterococci in Nigeria have only reported *E. faecalis*[@ref1],[@ref22]. Ampicillin and Ciprofloxacin resistance were exhibited by the *vanA* and *vanB* isolates as also found in other studies[@ref23],[@ref24], whereas high-level resistance to gentamicin occurred only in the *vanB* isolates and two *van C* isolates. This rate of high-level resistance to gentamicin is comparable to that of an earlier study in this institution[@ref1]. All VRE isolates remained susceptible to linezolid similar to the findings of a study in South America25. Linezolid is a very attractive antimicrobial therapy for VRE infections due to its favorable pharmacokinetic distribution, low incidence of adverse effects, and oral bioavailability[@ref26], however, resistance to this agent has begun to emerge[@ref26],[@ref27].

Apart from the ward of admission, no other risk factor showed significant association with VRE colonization by Univariate analysis suggesting the possibility of nosocomial transmission. This may however be due to the relatively small number of patients who were colonized with VRE. The low prevalence of VRE will require larger studies to fully elucidate risk factors for VRE colonization in Nigeria.

The findings of this study reveals the potential for the spread of Vancomycin Resistant Enterococci among patients in this center as well as the need for continuous surveillance and laboratory testing for Vancomycin resistance in enterococcal isolates for early identification of potential outbreaks of VRE infections, and institution of control measures.

This study clearly shows that the prevalence of VRE is still low in Nigeria, giving Nigeria the opportunity to combat the emergence of VRE by measures such as antibiotic stewardship program and other infection control strategies.
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